Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression

Du,Yanhua; Wu,Jun; Zhang,Haiyan; Li,Shaobo; Sun,Hong

doi:10.3892/mmr.2017.6183

Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression

Authors:
- Yanhua Du
- Jun Wu
- Haiyan Zhang
- Shaobo Li
- Hong Sun
View Affiliations

Affiliations: Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, P.R. China, Pathology Center, Shanghai General Hospital/Faculty of Basic Medicine, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China
Published online on: February 8, 2017 https://doi.org/10.3892/mmr.2017.6183
Pages: 1638-1646
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The silent information regulator 2 related enzyme 2 (SIRT2) has been reported to have an important role in tumorigenesis. Although two distinct effects of SIRT2 have recently been revealed, which explain opposing expression patterns in different types of cancer, the specific function of SIRT2 in ovarian cancer remains unknown. The present study investigated the expression of SIRT2 in serous ovarian carcinoma (SOC) and its pathogenic mechanism. It was observed that SIRT2 expression in SOC was significantly downregulated when compared with ovarian surface epithelium via western blot and immunohistochemistry. Statistical analysis revealed that attenuated expression of SIRT2 was associated with the International Federation of Gynecology and Obstetrics classification of ovarian cancer. Reduced SIRT2 expression during tumorigenesis failed to repress cyclin‑dependent kinase 4 expression, which eventually led to accelerated cell proliferation. Furthermore, the wound healing assay and Transwell assay determined that reduced expression of SIRT2 promoted SOC cell migration and invasion. In conclusion, the results of the current study suggest that SIRT2 has a tumor‑suppressor function in ovarian cells and it might be a viable target for further SOC treatment.

View Figures

View References

1	Vargas-Hernández VM, Moreno-Eutimio MA, Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Imai S, Armstrong CM, Kaeberlein M and Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000. View Article : Google Scholar : PubMed/NCBI
4	Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K and Skokowa J: The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 97:551–559. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wilson JM, Le VQ, Zimmerman C, Marmorstein R and Pillus L: Nuclear export modulates the cytoplasmic Sir2 homologue Hst2. EMBO Rep. 7:1247–1251. 2006. View Article : Google Scholar : PubMed/NCBI
6	Cha YI and Kim HS: Emerging role of sirtuins on tumorigenesis: Possible link between aging and cancer. BMB Rep. 46:429–438. 2013. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Dai D, Lu Q, Fei M, Li M and Wu X: Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21 axis. Biochem Biophys Res Commun. 441:661–667. 2013. View Article : Google Scholar : PubMed/NCBI
8	Karwaciak I, Gorzkiewicz M, Ryba K, Dastych J, Pulaski L and Ratajewski M: AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation. Chem Biol Interact. 236:9–18. 2015. View Article : Google Scholar : PubMed/NCBI
9	Chen J, Chan AW, To KF, Chen W, Zhang Z, Ren J, Song C, Cheung YS, Lai PB, Cheng SH, et al: SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology. 57:2287–2298. 2013. View Article : Google Scholar : PubMed/NCBI
10	Pizarro JG, Folch J, Esparza JL, Jordan J, Pallàs M and Camins A: A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286. J Cell Mol Med. 13:3906–3917. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang P, Xu YH, Dong B, Xiong Y, Lei QY and Guan KL: Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 23:464–476. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, Watanabe T, Ohama E, Tahimic CG, Kurimasa A and Oshimura M: Proteomics-based identification of differentially expressed genes in human gliomas: Down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 309:558–566. 2003. View Article : Google Scholar : PubMed/NCBI
13	Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, et al: A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction and gastric cardia. Gastroenterology. 139:1995–2004.e15. 2010. View Article : Google Scholar : PubMed/NCBI
14	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C and Wölfel T: The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA. 102:16013–16018. 2005. View Article : Google Scholar : PubMed/NCBI
15	Li Z, Xie QR, Chen Z, Lu S and Xia W: Regulation of SIRT2 levels for human non-small cell lung cancer therapy. Lung Cancer. 82:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
16	Xu W, Jiang K, Shen M, Qian Y and Peng Y: SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A. Biol Chem. 396:929–936. 2015. View Article : Google Scholar : PubMed/NCBI
17	Mangas-Sanjuan V, Oláh J, Gonzalez-Alvarez I, Lehotzky A, Tőkési N, Bermejo M and Ovádi J: Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. Br J Pharmacol. 172:829–840. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang F, Chan CH, Chen K, Guan X, Lin HK and Tong Q: Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene. 31:1546–1557. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hoffmann G, Breitenbücher F, Schuler M and Ehrenhofer-Murray AE: A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 289:5208–5216. 2014. View Article : Google Scholar : PubMed/NCBI
20	Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, et al: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 20:487–499. 2011. View Article : Google Scholar : PubMed/NCBI
21	Jiang W, Wang S, Xiao M, Lin Y, Zhou L, Lei Q, Xiong Y, Guan KL and Zhao S: Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell. 43:33–44. 2011. View Article : Google Scholar : PubMed/NCBI
22	Tobin NP, Foukakis T, De Petris L and Bergh J: The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. J Intern Med. 278:545–570. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wu J, Zhang YC, Suo WH, Liu XB, Shen WW, Tian H and Fu GH: Induction of anion exchanger-1 translation and its opposite roles in the carcinogenesis of gastric cancer cells and differentiation of K562 cells. Oncogene. 29:1987–1996. 2010. View Article : Google Scholar : PubMed/NCBI
24	Cui Y, Li SB, Peng XC, Wu J and Fu GH: Trastuzumab inhibits growth of HER2-negative gastric cancer cells through gastrin-initialized CCKBR signaling. Dig Dis Sci. 60:3631–3641. 2015. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, et al: The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 20:503–514. 2013. View Article : Google Scholar : PubMed/NCBI
27	Lin R, Tao R, Gao X, Li T, Zhou X, Guan KL, Xiong Y and Lei QY: Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell. 51:506–518. 2013. View Article : Google Scholar : PubMed/NCBI
28	Dickson MA: Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 20:3379–3383. 2014. View Article : Google Scholar : PubMed/NCBI
29	Nezhat FR, Apostol R, Nezhat C and Pejovic T: New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 213:262–267. 2015. View Article : Google Scholar : PubMed/NCBI
30	Zeppernick F and Meinhold-Heerlein I: The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014. View Article : Google Scholar : PubMed/NCBI
31	Zapardiel I, Diestro MD and Aletti G: Conservative treatment of early stage ovarian cancer: Oncological and fertility outcomes. Eur J Surg Oncol. 40:387–393. 2014. View Article : Google Scholar : PubMed/NCBI
32	Jackson AL, Eisenhauer EL and Herzog TJ: Emerging therapies: Angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs. 20:331–346. 2015. View Article : Google Scholar : PubMed/NCBI
33	Rutten MJ, Boldingh JH, Schuit E, Trum H, van Driel W, Mol BW, Kenter GG and Buist MR: Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer. Gynecol Oncol. 135:13–18. 2014. View Article : Google Scholar : PubMed/NCBI
34	Pandithage R, Lilischkis R, Harting K, Wolf A, Jedamzik B, Lüscher-Firzlaff J, Vervoorts J, Lasonder E, Kremmer E, Knöll B and Lüscher B: The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol. 180:915–929. 2008. View Article : Google Scholar : PubMed/NCBI
35	Sui L, Dong Y, Ohno M, Goto M, Inohara T, Sugimoto K, Tai Y, Hando T and Tokuda M: Inverse expression of Cdk4 and p16 in epithelial ovarian tumors. Gynecol Oncol. 79:230–237. 2000. View Article : Google Scholar : PubMed/NCBI
36	Wang H, Goode T, Iakova P, Albrecht JH and Timchenko NA: C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J. 21:930–941. 2002. View Article : Google Scholar : PubMed/NCBI
37	Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 1602:73–87. 2002.PubMed/NCBI